Vienna, Austria

Hans-Peter Schwarz

USPTO Granted Patents = 105 

 

 

Average Co-Inventor Count = 4.6

ph-index = 14

Forward Citations = 735(Granted Patents)


Inventors with similar research interests:


Company Filing History:


Years Active: 1996-2025

Loading Chart...
Loading Chart...
Loading Chart...
105 patents (USPTO):

Title: Unveiling the Innovative Mind of Inventor Hans-Peter Schwarz

Introduction:

In the realm of patents and innovations, Vienna-based inventor Hans-Peter Schwarz shines brightly with a remarkable portfolio of 103 patents. His groundbreaking work has revolutionized the field of plasma-derived protein compositions, particularly in the realm of reducing serine protease and serine protease zymogen content.

Latest Patents:

1. Removal of serine proteases by treatment with finely divided silicon dioxide: Schwarz's inventive methods offer novel ways to decrease serine protease and serine protease zymogen content in plasma-derived protein compositions. These innovative techniques pave the way for manufacturing compositions with reduced serine protease content, benefitting the treatment, management, and prevention of various diseases.

2. Stabilized liquid and lyophilized ADAMTS13 formulations: Schwarz's formulations of ADAMTS13 boast enhanced properties suitable for pharmaceutical administration. These formulations address diseases and conditions linked to VWF and ADAMTS13 dysfunction, offering new avenues for treatment. Additionally, kits comprising ADAMTS13 formulations further expand the scope of potential applications.

Career Highlights:

Throughout his illustrious career, Hans-Peter Schwarz has lent his expertise to prominent companies such as Baxalta GmbH and Baxter International Inc. His innovative prowess and dedication have left an indelible mark on the field, cementing his status as a thought leader in pharmaceutical innovation.

Collaborations:

In his journey towards pioneering advancements, Schwarz has collaborated with esteemed colleagues, including Peter Turecek and Wolfgang Teschner. Together, they have synergized their talents and knowledge to drive forward cutting-edge research and development initiatives.

Conclusion:

Inventor Hans-Peter Schwarz's tireless commitment to innovation and his invaluable contributions to the realm of plasma-derived protein compositions underscore his position as a visionary in the field of pharmaceuticals. With a rich tapestry of patents and a legacy of collaboration with industry experts, Schwarz continues to shape the landscape of medical advancements with his inventive spirit and unwavering dedication.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…